The competitive landscape in digital neurological care is surprisingly thin. Mental health apps are everywhere. General telehealth platforms are abundant. But structured specialty care for migraine and concussion? Almost nobody is doing it at scale with real clinical infrastructure behind it. That gap gives Hemi time to establish itself before larger players notice the opportunity.

The team's clinical depth is Hemi's real moat. Building a digital platform is a software problem. Building a digital platform that neurologists trust enough to integrate into their clinical practice is a clinical problem. The founding team spans both domains, which is why the platform feels designed by clinicians rather than bolted onto a generic telehealth framework.

Migraine is the third most prevalent disease on the planet. Over a billion people live with it. The average patient waits years for a proper diagnosis, cycles through multiple GPs and specialists, and ends up managing symptoms rather than following a structured treatment plan. The care pathway isn't broken. There isn't really a pathway at all.

Hemi Health wants to build one. The Copenhagen-based startup just closed a EUR 4 million seed round led by EIFO (Denmark's export and investment fund) and Swiss Health Ventures, with continued backing from Sondo Capital, Alliance Venture Capital, and Crowberry Capital. The money will fund expansion into the Netherlands, Hemi's first market outside Denmark, and accelerate development of its AI-powered clinical platform.

What makes Hemi different from the flood of digital health apps that promise to track your headaches? It actually employs neurologists. The company runs physical clinics in Frederiksberg, Aarhus, and Middelfart while delivering a significant portion of care digitally through video consultations and its proprietary app. Hybrid model. Real doctors. Structured protocols.

The economic burden of migraine is staggering and widely underappreciated. In Europe alone, migraine costs an estimated EUR 110 billion annually in lost productivity, healthcare expenses, and reduced quality of life. It's the leading cause of disability in people under 50. Yet most healthcare systems treat it as a nuisance rather than a serious neurological condition deserving structured clinical pathways.

That disconnect between disease burden and care quality is where Hemi operates. The company isn't trying to invent new treatments. The clinical knowledge for managing migraine effectively already exists. The problem is delivery. Getting the right combination of medication management, lifestyle modification, physiotherapy, and psychological support to each patient in a coordinated way is something most healthcare systems simply can't do at scale. Hemi's platform is designed to systematize that coordination.

Hemi was founded in 2023 by Anna Lofqvist, Benedicte Grytte Dahl, Sune K-Holm Nielsen, and Mathias Buch Iversen. Lofqvist, who lives with migraine herself, co-founded the company after experiencing firsthand how exhausting complex neurological care pathways can be. "Across neurological conditions, people often face the same challenge," she says. "Navigating care without clarity or continuity. We built Hemi to meet people where they are."

That personal stake shows up in the product design. Hemi's model centers on structured diagnostics, individualized treatment plans, and continuous monitoring. Patients don't just get a prescription and a follow-up appointment in three months. They get week-by-week protocols with documented progress, psychoeducation about their condition, and support for graded return-to-work or education processes. The treatment documentation can be shared, with patient consent, with employers or insurance providers.

It's the kind of approach that sounds obvious when you describe it but barely exists in practice. Most neurological care is episodic. You see a specialist when things get bad, get a treatment adjustment, then disappear until the next crisis. Hemi is trying to flip that into continuous, structured care that generates measurable outcomes.

Hemi doesn't limit itself to migraine. The platform also treats long-term symptoms from concussion and whiplash, conditions that share a similar problem: fragmented care, inconsistent follow-up, and patients who fall through the cracks of a system not designed for chronic complexity.

Concussion treatment is a particularly interesting expansion. Post-concussion syndrome affects an estimated 15 to 30 percent of concussion patients, with symptoms persisting for months or years. There's no standard care pathway in most European healthcare systems. Patients bounce between neurologists, physiotherapists, psychologists, and occupational therapists without anyone coordinating the overall treatment plan.

Hemi's multidisciplinary model, combining neurology, digital monitoring, and coordinated rehabilitation, is designed to fill that gap. The company positions itself as a specialty care provider that insurance systems can contract with directly, rather than a consumer wellness app trying to monetize engagement.

EIFO co-leading this round is notable. Denmark's export and investment fund has been increasingly active in healthtech, backing companies that combine clinical expertise with scalable digital platforms. The fund's Claudia Maria Colciago called Hemi's technology "exactly" what migraine care needs, emphasizing the team's focus on root causes rather than symptoms.

Swiss Health Ventures brings a different angle. The Zurich-based firm specializes in digital health companies expanding across European markets, which aligns perfectly with Hemi's Netherlands expansion plan. The Swiss investor's portfolio includes several companies navigating the complexities of cross-border healthcare regulation, experience that will matter as Hemi moves beyond Denmark.

Crowberry Capital, the Icelandic VC firm continuing its investment, adds another Nordic node to the cap table. The round reads like a deliberate assembly of investors who can help Hemi navigate different European healthcare systems rather than just write checks.

CTO Mathias Buch Iversen sees AI as the layer that makes Hemi's model scale. "The possibilities AI gives us in complex care are substantial," he says. "Used correctly, it can transform fragmented, multi-year care journeys into structured programs with clear progression and measurable outcomes."

The emphasis on "used correctly" is telling. The digital health space is littered with companies that slapped AI onto a symptom tracker and called it innovation. Hemi's approach is different because the AI sits within a clinical workflow operated by actual neurologists. It's decision support and treatment optimization, not a consumer-facing chatbot pretending to be a doctor.

That distinction matters for insurance alignment. European healthcare systems, whether single-payer or insurance-based, are increasingly willing to pay for digital care that demonstrates measurable clinical outcomes. They're much less interested in funding wellness apps with fuzzy metrics. Hemi's structured treatment documentation gives insurers exactly the kind of data they need to justify reimbursement.

The choice of the Netherlands as Hemi's first international market isn't random. The Dutch healthcare system is insurance-based with a strong tradition of contracting specialized care providers. Migraine prevalence is high. And the market is small enough to serve as a proof point without requiring the kind of regulatory infrastructure needed to launch in Germany or France.

If Hemi can demonstrate that its hybrid model, clinics plus digital platform, delivers better outcomes at lower cost than traditional fragmented care, the expansion playbook writes itself. Every European country has the same problem: too many migraine patients, too few neurologists, and no structured care pathway connecting them.

Hemi's decision to position itself within insurance-aligned healthcare systems rather than as a direct-to-consumer wellness company is a strategic choice that deserves attention. The European digital health graveyard is full of companies that built beautiful consumer apps, acquired users cheaply, and then couldn't figure out who would actually pay for the service. Insurance alignment solves the payment question from day one.

Insurers want two things from digital health providers: evidence that the treatment works and documentation that proves it. Hemi's structured protocols generate both automatically. Every patient interaction, every treatment adjustment, every outcome measurement is captured in the platform. That creates the kind of real-world evidence that insurance companies need to justify reimbursement rates and that academic researchers need to advance clinical understanding of treatment effectiveness.

Three clinics in Denmark is a start. But the real test is whether Hemi's model can scale without losing the clinical quality that makes it work. Digital delivery helps: a significant portion of patient interactions happen through video consultations and the app, which means expanding to new markets doesn't necessarily require building physical clinics everywhere. The Netherlands expansion will test a hybrid model where digital care is primary and in-person visits happen at partner facilities.

The broader market context favors Hemi's timing. European governments are actively seeking ways to reduce healthcare costs while improving outcomes for chronic conditions. Migraine alone costs healthcare systems billions annually in direct treatment expenses and indirect productivity losses. A structured digital care platform that can demonstrate reduced emergency visits, fewer unnecessary specialist referrals, and faster return-to-work outcomes has a clear value proposition for payers. That's the evidence Hemi needs to generate in the Netherlands to unlock larger markets like Germany, France, and the UK.

EUR 4 million is a modest seed round by healthtech standards. It won't fund clinics across Europe. But it'll fund the proof that structured, AI-enhanced neurological care can work outside Denmark. For the billion people worldwide living with migraine, that proof can't come soon enough.